Market Overview

Benzinga's Top Upgrades, Downgrades For August 18, 2020

Share:

Upgrades

  • Wedbush upgraded the previous rating for Best Buy Co Inc (NYSE: BBY) from Neutral to Outperform. For the first quarter, Best Buy Co had an EPS of $0.67, compared to year-ago quarter EPS of $1.02. At the moment, the stock has a 52-week-high of $111.39 and a 52-week-low of $48.10. Best Buy Co closed at $110.77 at the end of the last trading period.
  • Cantor Fitzgerald upgraded the previous rating for Curaleaf Holdings Inc (OTC: CURLF) from Neutral to Overweight. Curaleaf Holdings earned $0.03 in the first quarter, compared to $0.02 in the year-ago quarter. The current stock performance of Curaleaf Holdings shows a 52-week-high of $9.66 and a 52-week-low of $2.54. Moreover, at the end of the last trading period, the closing price was at $9.43.
  • For Barings BDC Inc (NYSE: BBDC), Keefe, Bruyette & Woods upgraded the previous rating of Market Perform to the current rating Outperform. For the second quarter, Barings BDC had an EPS of $0.14, compared to year-ago quarter EPS of $0.15. At the moment, the stock has a 52-week-high of $10.59 and a 52-week-low of $4.67. Barings BDC closed at $8.30 at the end of the last trading period.
  •  

Downgrades

  • According to Argus Research, the prior rating for Howmet Aerospace Inc (NYSE: HWM) was changed from Buy to Hold. Howmet Aerospace earned $0.12 in the second quarter, compared to $0.58 in the year-ago quarter. At the moment, the stock has a 52-week-high of $18.99 and a 52-week-low of $9.87. Howmet Aerospace closed at $17.35 at the end of the last trading period.
  • For AMAG Pharmaceuticals Inc (NASDAQ: AMAG), Barclays downgraded the previous rating of Overweight to the current rating Equal-Weight. AMAG Pharmaceuticals earned $0.57 in the second quarter, compared to $1.14 in the year-ago quarter. The stock has a 52-week-high of $13.53 and a 52-week-low of $4.41. At the end of the last trading period, AMAG Pharmaceuticals closed at $10.89.
  • Oppenheimer downgraded the previous rating for Intercontinental Exchange Inc (NYSE: ICE) from Outperform to Perform. For the second quarter, Intercontinental Exchange had an EPS of $1.07, compared to year-ago quarter EPS of $0.94. The current stock performance of Intercontinental Exchange shows a 52-week-high of $104.30 and a 52-week-low of $63.51. Moreover, at the end of the last trading period, the closing price was at $104.07.
  • For Montage Resources Corp (NYSE: MR), Johnson Rice downgraded the previous rating of Buy to the current rating Hold. At the moment, the stock has a 52-week-high of $8.30 and a 52-week-low of $1.99. Montage Resources closed at $5.51 at the end of the last trading period.
  • According to Citigroup, the prior rating for Nabors Industries Ltd (NYSE: NBR) was changed from Neutral to Sell. For the second quarter, Nabors Industries had an EPS of $14.45, compared to year-ago quarter EPS of $0.41. At the moment, the stock has a 52-week-high of $87.00 and a 52-week-low of $0.20. Nabors Industries closed at $46.45 at the end of the last trading period.
  • For Unity Biotechnology Inc (NASDAQ: UBX), Morgan Stanley downgraded the previous rating of Overweight to the current rating Equal-Weight. Unity Biotechnology earned $0.38 in the second quarter, compared to $0.56 in the year-ago quarter. At the moment, the stock has a 52-week-high of $15.44 and a 52-week-low of $4.05. Unity Biotechnology closed at $4.15 at the end of the last trading period.
  • Morgan Stanley downgraded the previous rating for Vonage Holdings Corp (NASDAQ: VG) from Overweight to Equal-Weight. Vonage Hldgs earned $0.04 in the second quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Vonage Hldgs shows a 52-week-high of $13.66 and a 52-week-low of $4.18. Moreover, at the end of the last trading period, the closing price was at $11.77.
  • SVB Leerink downgraded the previous rating for Principia Biopharma Inc (NASDAQ: PRNB) from Outperform to Market Perform. The current stock performance of Principia Biopharma shows a 52-week-high of $99.38 and a 52-week-low of $25.35. Moreover, at the end of the last trading period, the closing price was at $99.25.

 

Initiations

  • With a current rating of Outperform, Wedbush initiated coverage on Inozyme Pharma Inc (NASDAQ: INZY). The price target seems to have been set at $35.00 for Inozyme Pharma. The current stock performance of Inozyme Pharma shows a 52-week-high of $31.27 and a 52-week-low of $17.25. Moreover, at the end of the last trading period, the closing price was at $29.00.
  • Needham initiated coverage on Nurix Therapeutics Inc (NASDAQ: NRIX) with a Buy rating. The price target for Nurix Therapeutics is set to $35.00. The current stock performance of Nurix Therapeutics shows a 52-week-high of $27.64 and a 52-week-low of $15.21. Moreover, at the end of the last trading period, the closing price was at $27.00.
  • Brookline Capital initiated coverage on 9 Meters Biopharma Inc (NASDAQ: NMTR) with a Buy rating. The price target for 9 Meters Biopharma is set to $5.00. 9 Meters Biopharma earned $0.57 in the second quarter, compared to $0.13 in the year-ago quarter. The stock has a 52-week-high of $0.82 and a 52-week-low of $0.44. At the end of the last trading period, 9 Meters Biopharma closed at $0.56.
  • JP Morgan initiated coverage on ITeos Therapeutics Inc (NASDAQ: ITOS) with an Overweight rating. The price target for ITeos Therapeutics is set to $40.00. At the moment, the stock has a 52-week-high of $32.98 and a 52-week-low of $17.50. ITeos Therapeutics closed at $32.92 at the end of the last trading period.
  • With a current rating of Buy, Citigroup initiated coverage on Digital Media Solutions Inc (NYSE: DMS). The price target seems to have been set at $12.00 for Digital Media Solutions. At the moment, the stock has a 52-week-high of $10.66 and a 52-week-low of $6.75. Digital Media Solutions closed at $8.41 at the end of the last trading period.
  • With a current rating of Buy, B of A Securities initiated coverage on Annexon Inc (NASDAQ: ANNX). The price target seems to have been set at $33.00 for Annexon. The stock has a 52-week-high of $29.71 and a 52-week-low of $15.33. At the end of the last trading period, Annexon closed at $26.55.
  • Wells Fargo initiated coverage on Voya Financial Inc (NYSE: VOYA) with an Overweight rating. The price target for Voya Finl is set to $62.00. For the second quarter, Voya Finl had an EPS of $1.09, compared to year-ago quarter EPS of $1.52. The stock has a 52-week-high of $63.81 and a 52-week-low of $29.75. At the end of the last trading period, Voya Finl closed at $51.22.
  • B of A Securities initiated coverage on Inozyme Pharma Inc (NASDAQ: INZY) with a Buy rating. The price target for Inozyme Pharma is set to $33.00. At the moment, the stock has a 52-week-high of $31.27 and a 52-week-low of $17.25. Inozyme Pharma closed at $29.00 at the end of the last trading period.
  • For Annexon Inc (NASDAQ: ANNX), Cowen & Co. initiated coverage, by setting the current rating at Outperform. The current stock performance of Annexon shows a 52-week-high of $29.71 and a 52-week-low of $15.33. Moreover, at the end of the last trading period, the closing price was at $26.55.
  • With a current rating of Overweight, Piper Sandler initiated coverage on ITeos Therapeutics Inc (NASDAQ: ITOS). The price target seems to have been set at $50.00 for ITeos Therapeutics. The current stock performance of ITeos Therapeutics shows a 52-week-high of $32.98 and a 52-week-low of $17.50. Moreover, at the end of the last trading period, the closing price was at $32.92.
  • Piper Sandler initiated coverage on Seres Therapeutics Inc (NASDAQ: MCRB) with an Overweight rating. The price target for Seres Therapeutics is set to $40.00. In the second quarter, Seres Therapeutics showed an EPS of $0.28, compared to $0.24 from the year-ago quarter. At the moment, the stock has a 52-week-high of $33.00 and a 52-week-low of $2.52. Seres Therapeutics closed at $26.16 at the end of the last trading period.
  • Needham initiated coverage on Personalis Inc (NASDAQ: PSNL) with a Buy rating. The price target for Personalis is set to $25.00. For the second quarter, Personalis had an EPS of $0.29, compared to year-ago quarter EPS of $0.89. The stock has a 52-week-high of $23.00 and a 52-week-low of $4.27. At the end of the last trading period, Personalis closed at $21.72.
 

Related Articles (AMAG + ANNX)

View Comments and Join the Discussion!

Posted-In: Initiations top upgradesPenny Stocks Upgrades Downgrades Initiation Intraday Update Analyst Ratings

Latest Ratings

StockFirmActionPT
TSLACitigroupMaintains137.0
SPOTDeutsche BankMaintains250.0
AMZNDeutsche BankMaintains4,050.0
DOCUBairdInitiates Coverage On280.0
ASOGuggenheimInitiates Coverage On17.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com